Non-Clinical Safety Lead - Cambridge, MA
UCB Inc. | |
United States, Massachusetts, Cambridge | |
Mar 30, 2026 | |
|
JOB DESCRIPTION Make your mark for patients To strengthen our Non-Clinical Safety Evaluation group within Early Clinical Development and Translational Science, we are looking for a talented individual for the role of Non-Clinical Safety Lead, based in Cambridge, MA (USA) About the role As a Non-clinical Safety Lead, you will provide scientific leadership for non-clinical safety across discovery and development programs. You will shape non-clinical strategies, ensure high-quality execution, and support regulatory interactions from early development through clinical progression and post approval. You will:
This role is well suited to an experienced toxicologist-ideally with exposure to gene and cell therapy or other novel modalities-who enjoys working at the interface of science, development strategy, and regulation. You will thrive in an environment where you can share expertise across functions and global UCB sites, engage with cutting-edge science and build collaborative networks to drive cross-functional success. What you'll do
Interested? For this role you'll need the following education, experience and skills
Preferred Qualifications:
Salary: This position's reasonably anticipated base salary range is $168,000 to $220,500 per year. The actual salary offered will consider internal equity and may also vary depending on the candidate's region, job-related knowledge, skills and experience, among other factors. Are you ready to 'go beyond' to create value and make your mark for patients? If this sounds like you, then we would love to hear from you! About us Why work with us? At UCB, we've embraced a hybrid-first approach to work, bringing teams together in local hubs to foster collaborative curiosity. Unless expressly stated in the description or precluded by the nature of the position, roles are hybrid with 40% of your time spent in the office. UCB is an equal opportunity employer. All employment decisions will be made without regard to any characteristic protected by applicable laws. | |
Mar 30, 2026